Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.68 |
| ▸ | OPRL1 | P41146 | 7/20 | 0.67 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.67 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.67 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.67 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.64 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22605436 | 0.85 | HSD17B10 (0.68) | HSD17B10OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL5962828 | 0.85 | HSD17B10 (0.68) | HSD17B10OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL5781495 | 0.84 | HSD17B10 (0.67) | HSD17B10OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL2539061 | 0.83 | OPRM1 (0.77) | HSD17B10OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL318707 | 0.82 | HSD17B10 (0.65) | HSD17B10OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL219618 | 0.81 | HSD17B10 (1.00) | HSD17B10OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL7587764 | 0.81 | HSD17B10 (1.00) | HSD17B10OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL5962890 | 0.81 | OPRM1 (0.79) | HSD17B10OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL21688403 | 0.81 | HSD17B10 (0.63) | HSD17B10OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL9912156 | 0.81 | OPRL1 (0.74) | HSD17B10OPRL1OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166124-A1 | TRICYCLIC SPIROCYCLE DERIVATIVES AND METHODS OF USE | MCCORMICK KEVIN D | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166124-A1 | TRICYCLIC SPIROCYCLE DERIVATIVES AND METHODS OF USE | GPR119, TRPV1, NR3C2 | HSD17B10 595/4885OPRL1 196/4885OPRM1 1209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.